Patient populations and targeted therapies
Targeted therapies, patient populations — today’s sixteen briefings run from charting the body’s molecules and genomes, to aiming precise treatments at the faults those maps reveal, to the patient populations who benefit.
Today DiseaseSignal published sixteen briefings — two in each of eight sections — and read together they trace a single arc: first map the biology, then target the fault the map reveals, then define who benefits. Naming that arc is the day's signal (analysis across the briefings, not a claim from any single study).
First, the maps
Several briefings are about measurement — the tools that make biology legible. The cryo-EM "resolution revolution" resolved protein structures at near-atomic detail; a mass-spectrometry draft charted the human proteome across tissues; ENCODE catalogued the genome's regulatory switches; and the first genome-wide association study showed how to find disease-linked variants across thousands of people at once. None of these treat a patient — they make the target findable.
Then, the targets
A second cluster aims precise therapies at a defined molecular fault. Imatinib blocks the BCR-ABL enzyme that drives chronic myeloid leukemia; trastuzumab targets the HER2 receptor overexpressed in a quarter of breast cancers; gene therapies supply a missing gene in inherited blindness and in hemophilia B; and engineered peptides — semaglutide, and parathyroid hormone for bone — turn the body's own signals into treatments. Each works only where the fault it targets is present, which is why biomarker and gene testing decide who receives them.
Then, the populations
A third cluster defines exactly who benefits. Low-dose CT screening cut lung-cancer deaths, but only in high-risk smokers; the SPRINT trial found a lower blood-pressure target helped high-risk adults without diabetes; the Mediterranean and DASH dietary patterns lowered cardiovascular risk and blood pressure; HIV treatment doubled as population-level prevention; and dexamethasone helped severe COVID-19 patients, but not milder ones.
The signal
The connective tissue is that precision depends on measurement: you can only target what you can map, and only help the right people if you can define them (this is analysis — a pattern to watch, not a settled result). The frontier is where the three meet. Nothing here is medical advice; each claim links to its briefing and primary source.